Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
NCT02014051
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
SyB C-1101
Sponsor
SymBio Pharmaceuticals